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Defining new approaches for the prevention and treatment of atherosclerosis is an important
priority. Recently, measurement of endothelial function in patients has emerged as a useful
tool for atherosclerosis research. Risk factors are associated with impaired endothelial
function, and clinical syndromes relate, in part, to a loss of endothelial control of vascular
homeostasis. Recent studies have shown that the severity of endothelial dysfunction relates to
cardiovascular risk. A growing number of interventions known to reduce cardiovascular risk
have been shown to improve endothelial function. This work suggests that studies of
endothelial function could be used in the care of patients and as a surrogate marker for the
evaluation of new therapeutic strategies. This article will review this growing literature in an
effort to evaluate the current clinical utility of endothelial dysfunction. (J Am Coll Cardiol
2003;42:1149–60) © 2003 by the American College of Cardiology Foundation
Measurement of endothelial function in patients has re-
cently emerged as a useful tool for atherosclerosis research.
In the setting of cardiovascular disease (CVD) risk factors,
the endothelium loses its normal regulatory functions.
Clinical syndromes such as stable and unstable angina, acute
myocardial infarction, claudication, and stroke relate, in
part, to a loss of endothelial control of vascular tone,
thrombosis, and the composition of the vascular wall.
Recent studies have shown that the severity of endothelial
dysfunction relates to the risk for an initial or recurrent
cardiovascular event. Finally, a growing number of interven-
tions known to reduce cardiovascular risk also improve
endothelial function. This work has prompted speculation
that endothelial function serves as a “barometer” for cardio-
vascular health that can be used for patient care and
evaluation of new therapeutic strategies (1). This article will
review this growing literature in an effort to evaluate the
current clinical utility of assessing endothelial dysfunction.
Normal functions of the endothelium. The endothelium
acts to maintain vascular homeostasis through multiple
complex interactions with cells in the vessel wall and lumen
(reviewed by Gokce et al. [2]). Table 1 lists many of the
major factors regulated and elaborated by vascular endothe-
lium. Specifically, the endothelium regulates vascular tone
by balancing production of vasodilators, including nitric
oxide (NO), and vasoconstrictors. Furthermore, the endo-
thelium controls blood fluidity and coagulation through the
production of factors that regulate platelet activity, the
clotting cascade, and the fibrinolytic system. Finally, the
endothelium has the capacity to produce cytokines and
adhesion molecules that regulate and direct the inflamma-
tory process (3).
Pathophysiology of endothelial dysfunction. Under ho-
meostatic conditions, the endothelium maintains normal
vascular tone and blood fluidity, and there is little to no
expression of pro-inflammatory factors. However, both
traditional and novel CVD risk factors initiate a chronic
inflammatory process that is accompanied by a loss of
vasodilator and anti-thrombotic factors and an increase in
vasoconstrictor and pro-thrombotic products. As outlined
in Figure 1, risk factors as diverse as smoking, aging,
hypercholesterolemia, hypertension, hyperglycemia, and a
family history of premature atherosclerotic disease are all
associated with an attenuation/loss of endothelium-
dependent vasodilation in both adults and children (2,4,5).
More recently recognized risk factors such as obesity (6),
elevated C-reactive protein (7), and chronic systemic infec-
tion (8) also are associated with endothelial dysfunction.
Abnormal vasoreactivity is not the only imbalance present
in high-risk individuals. Endothelial cells may adopt a
pro-thrombotic phenotype, portending an elevated risk of
cardiovascular events in high-risk individuals (9,10). Fur-
thermore, when exposed to certain pathogenic pro-
inflammatory stimuli, the endothelium expresses leukocyte
chemotactic factors, adhesion molecules, and inflammatory
cytokines (11). The precise extent and order in which the
normal control mechanisms are affected have yet to be fully
elucidated.
The term “endothelial dysfunction” refers to this broad
alteration in endothelial phenotype that may contribute to
the development and clinical expression of atherosclerosis
(12). While the precise mechanisms remain to be eluci-
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dated, endothelial dysfunction appears to participate in a
“positive feedback loop” in which inflammatory factors
promote monocyte and T-cell adhesion, foam cell forma-
tion, extracellular matrix digestion, and vascular smooth
muscle migration and proliferation leading to atheroscle-
rotic plaque formation (3,13). Endothelial dysfunction also
is relevant to the later stages of the disease, and appears to
play a role in acute coronary syndromes (14). Given this
possible causal pathway from endothelial dysfunction to
atherosclerosis (Fig. 1), numerous methods have been em-
ployed to measure endothelial dysfunction in humans.
Methods of evaluating endothelial dysfunction in humans.
While atherosclerosis is associated with a broad alteration in
endothelial phenotype, the assessment of endothelium-
dependent vasodilation has emerged as an accessible indi-
cator of endothelial health. In particular, stimuli that in-
crease production of endothelium-derived NO have proven
useful in assessing endothelium-dependent vasodilation in
humans. Such stimuli include increased shear stress from
increased blood flow, and receptor-dependent agonists, such
as acetylcholine, bradykinin, or substance P. Basal NO
release can be assessed using specific inhibitors of NO
synthase, such as NG-monomethyl-L-arginine. Investiga-
tors have employed several methods in the evaluation of
endothelial function, each with its own advantages and
disadvantages (Table 2).
The earliest studies of endothelial control of vasomotion
used quantitative coronary angiography to examine the
vasomotor responses of the epicardial coronary artery during
infusion of acetylcholine (15) or increased blood flow (16).
In healthy individuals, the endothelium responds to these
stimuli by releasing vasodilator factors, particularly NO.
Early studies demonstrated that patients with angiographi-
cally proven coronary artery disease (CAD) display impaired
flow-mediated dilation (FMD) and a vasoconstrictor re-
sponse to acetylcholine rather than the normal vasodilator
response, likely reflecting loss of NO and unopposed con-
strictor effects of acetylcholine on vascular smooth muscle
(15). More recent studies suggest that acetylcholine-
mediated coronary constriction may also result, in part, from
enhanced endothelial release of the potent vasoconstrictor
endothelin (17).
Invasive studies in the arm involve infusion of endothelium-
dependent agonists into the brachial artery and measuring
the vasodilator responses of forearm resistance vessels using
venous occlusion plethysmography (18). Like studies in the
coronary circulation, this approach allows investigators to
examine dose-response relations and use specific agonists
and antagonists in a more accessible vascular bed. However,
the technique requires an arterial catheter and, thus, has
limited applicability for large-scale studies or future devel-
opment as a clinical tool.
Measures of arterial stiffness, including pulse wave veloc-
ity and arterial distensibility, are also being investigated as
non-invasive means of measuring vascular health (19).
Several studies have demonstrated that such measures pre-
dict cardiovascular events (20,21). While dynamic factors,
such as release of endothelium-derived NO, play a role,
arterial stiffness is also highly dependent on fixed structural
features of the vascular wall including the degree of fibrosis
and calcification (19). Elucidation of the precise relationship
between endothelial function and vascular stiffness awaits
further study.
Finally, there has been considerable interest in non-
invasive examination of endothelium-dependent FMD of
the conduit brachial artery using vascular ultrasound (22).
This response has been shown to depend in large part on
NO synthesis (23,24), but also reflects release of other
endothelium-derived vasodilators. Like measures of vascular
stiffness, this technique can safely be applied to large and
varied groups of patients and can be used to make repeated
measurements over time. As in the coronary circulation,
endothelial function in the brachial circulation is impaired
in the setting of traditional and novel risk factors and
responds to interventions known to reduce CVD risk (1).
Importantly, studies suggest that endothelial function de-
tected non-invasively in the brachial artery correlates with
function in conduit coronary arteries (25). Despite the many
Abbreviations and Acronyms
BP  blood pressure
CAD  coronary artery disease
CVD  cardiovascular disease
FMD  flow-mediated dilation
HRT  hormone replacement therapy
ICAM  intercellular adhesion molecule
NO  nitric oxide
VCAM-1  vascular cell adhesion molecule-1
Table 1. Normal Functions of the Vascular Endothelium and a
Partial List of Factors Elaborated and Regulated by the
Endothelium to Maintain Vascular Homeostasis
Maintenance of vascular tone
Nitric oxide
Prostaglandins (prostacyclin [PGI2], thromboxane A2 [TxA2])
Endothelial hyperpolarizing factor
Endothelin-1
Angiotensin II
C-type natriuretic peptide
Balancing blood fluidity and thrombosis
Nitric oxide
Tissue plasminogen activator
Heparins
Thrombomodulin
Prostaglandins
Plasminogen activator inhibitor-1 (PAI-1)
Tissue factor
Von Willibrand’s factor
Control of the vascular inflammatory process
Monocyte chemotactic factor-1 (MCP-1)
Adhesion molecule expression (VCAM-1, ICAM-1, selectins)
Interleukins 1, 6, and 18
Tumor necrosis factor
ICAM-1  intercellular adhesion molecule-1; VCAM-1  vascular cell adhesion
molecule-1.
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parallel findings, one modest-sized study suggested that,
within individual subjects, brachial artery FMD does not
correlate with resistance vessel (microvascular) function as
measured by infusion studies (26). Indeed, it is likely that
there is differential regulation of vascular tone in conduit
and resistance vessels, and that the different measures of
vascular function may have relevance to different aspects of
CVD.
Studies evaluating the prognostic value of endothelial
dysfunction. Although case-control studies indicate an
association between endothelial dysfunction and acute cor-
onary syndromes (14), more convincing evidence for a
pathogenic role is provided by studies demonstrating that
endothelial dysfunction identifies patients at increased risk
for future events. To date, 10 published studies have
examined this issue (Table 3).
Three studies evaluated the prognostic value of endothe-
lial dysfunction in the coronary circulation in patients with
CAD (27–29). In each study, endothelial dysfunction pre-
dicted the occurrence of CVD events, such as cardiac death,
myocardial infarction, unstable angina, ischemic stroke, and
revascularization procedures, after controlling for known
risk factors. The studies are limited because there was no
prospective plan to obtain long-term follow-up at the time
of enrollment and because the methods for studying endo-
thelial function may have evolved over time. Nevertheless,
these three studies involved a sizable number of patients and
had consistent results. The study by Halcox et al. (29) is
particularly convincing because of the larger sample size and
because the combined end point did not involve revascular-
ization procedures, which, unlike spontaneous cardiovascu-
lar events, are more likely to be influenced by non-biological
factors. In these studies, it is interesting that future events
were poorly predicted by the angiographic severity of
disease.
Two additional studies involved patients with CAD, but
examined endothelial dysfunction in the brachial rather than
coronary circulation. Heitzer et al. (30) observed that the
forearm blood flow responses to intra-arterial acetylcholine
was an independent predictor of cardiovascular events,
further suggesting that the forearm circulation is a reason-
able surrogate for the coronary circulation. These investiga-
tors also examined the degree to which a concomitant
ascorbic acid infusion improved endothelial function. Pa-
tients with the largest improvement in endothelial function
during ascorbic acid infusion had the highest risk, suggest-
ing that increased oxidative stress may be a contributing
mechanism for endothelial dysfunction and events. Neun-
teufl et al. (31) examined brachial artery FMD using
ultrasound. Although limited by a relatively small sample
size, retrospective design, and a heterogeneous mix of stable
and unstable patients, this study also suggested that endo-
thelial dysfunction in the brachial artery has prognostic
value.
Gokce et al. (32) prospectively examined patients with
atherosclerotic peripheral arterial disease awaiting non-
emergent vascular surgery. Such patients are known to have
a high incidence of recognized and undiagnosed CAD, and
Figure 1. The role of endothelial dysfunction in the pathogenesis of cardiovascular disease events. Cardiovascular disease risk factors adversely affect a
diverse range of endothelial homeostatic functions and contribute mechanistically to the development, progression, and clinical expression of atherosclerosis.
The response of the endothelium to the cumulative effects of risk factors may, in part, relate to intrinsic and environmental factors such as genetic
polymorphisms, dietary factors, exercise, and other factors. Thus, endothelial function may serve as a barometer for cardiovascular risk.
1151JACC Vol. 42, No. 7, 2003 Widlansky et al.
October 1, 2003:1149–60 Endothelial Dysfunction
they have high short-term post-operative risk. Endothelial
function was determined by brachial ultrasound before
surgery, and patients were followed for 30 days after surgery.
The study demonstrated that impaired FMD was a strong
independent predictor of post-operative events. The post-
operative state is associated with pain, fluid shifts, increased
sympathetic nervous system activity, and inflammation, and,
in this setting, endothelial dysfunction might increase the
risk for plaque rupture or a mismatch between myocardial
oxygen demand and supply. On longer term follow-up
(mean of 1.2 years), impaired brachial artery FMD re-
mained an independent predictor of events, even after the
patients had recovered from the immediate stress of surgery
(33). Notably, the study demonstrated that this non-
invasive method for studying endothelial function had high
sensitivity and negative predictive value, suggesting that it
might have utility as a screening test to identify low-risk
patients who might undergo surgery without further evalu-
ation.
In addition to studies that examined patients with estab-
lished atherosclerosis, several studies have examined the
prognostic value of endothelial function in patients with risk
factors, but no known atherosclerosis. Two of these studies
were done in the brachial artery (34,35). Perticone et al. (34)
examined the forearm blood flow responses to acetylcholine
in untreated male and female patients with hypertension,
and observed that endothelial dysfunction identified pa-
tients at risk. Modena et al. (35) examined brachial artery
FMD in post-menopausal women with newly diagnosed
hypertension. Patients had increased risk over the next five
years when endothelial dysfunction was not reversed by six
months of antihypertensive therapy. Although treatment
was not standardized, the type of antihypertensive therapy
or the degree of blood pressure (BP) lowering did not
explain the difference in prognosis. Importantly, these two
studies raise the possibility that endothelial function could
be used as a screening test for the primary prevention of
CVD and as a guide to therapy.
Studies in patients with angiographically normal coronary
arteries provide further evidence that endothelial dysfunc-
tion precedes and portends the development of athero-
sclerosis. Halcox et al. (29) found both epicardial and
microvascular endothelial dysfunction predicted future car-
diovascular events independently of the angiographic pres-
ence of CAD at the time of enrollment. Recently, Schindler
et al. (36) reported that a coronary vasoconstrictor response
to the cold pressor test, which reflects, in part, endothelial
dysfunction, independently predicts future cardiovascular
events in patients with normal coronary angiograms and
elevated C-reactive protein levels.
Overall, the 10 studies examining the prognostic value of
endothelial vasomotor function involved 1,920 patients with
atherosclerosis or hypertension and 333 patients with
events. These studies strongly and consistently demonstrate
that endothelial dysfunction identifies patients who have
increased risk for CVD events in the short and long term.
Importantly, endothelial vasomotor dysfunction appears to
be a systemic process that can be identified in vascular beds
remote from the coronary and cerebral circulations where
events occur.
In addition, vasomotor dysfunction, circulating blood
markers of endothelial dysfunction, also have prognostic
value. In patients without known CVD, elevated levels of
soluble intercellular adhesion molecule (ICAM) (37), and
tissue plasminogen activator (9), are independent predictors
of future cardiovascular events. In patients with known
coronary disease, soluble ICAM (38), von Willebrand factor
(39), tissue plasminogen activator (39), plasminogen activa-
tor inhibitor (40), and endothelin (41) all have prognostic
value. As mentioned previously, markers of systemic inflam-
Table 2. Advantages and Disadvantages of Methods to Quantify
Endothelial Function in Humans
1. Intracoronary agonist infusion with quantitative coronary angiography
Advantages
Direct quantification of endothelial function in the vascular bed
of interest
Allows for mapping dose-response relationships of endothelial
agonists and antagonists
Allows for examination of basal endothelial function (with NOS
antagonist infusion)
Disadvantages
Invasive
Expensive
Carries risks inherent with coronary artery catheterization
(stroke, MI, infection, vascular injury)
2. Brachial artery catheterization with venous occlusive plethysmography
Advantages
More accessible circulation than coronary arteries
Allows for mapping dose-response relationships of endothelial
agonists and antagonists
Allows for examination of basal endothelial function (with NOS
antagonist infusion)
Disadvantages
Invasive
Risk of median nerve injury, infection, vascular injury
3. Vascular tonometry and measurements of vascular stiffness
Advantages
Noninvasive
Safer and faster than either invasive method
Lower operator dependence than brachial artery ultrasound
May reflect basal endothelial function
Disadvantages
Importantly influenced by structural aspects of the vasculature
beyond the endothelium
4. Brachial artery ultrasound with FMD
Advantages
Noninvasive
Safer and faster than either invasive method
Reactivity correlates to endothelial dysfunction in coronary
circulation
Flow is a physiological stimulus for vasodilation unlike
agonists such as acetylcholine
Disadvantages
Poor resolution relative to arterial size
Variability in measurements
Highly operator-dependent
FMD  flow-mediated dilation; MI  myocardial infarction; NOS  nitric oxide
synthase.
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Table 3. Studies Evaluating the Predictive Value of Endothelial Dysfunction
Lead Author
Design/
Mean Follow-Up Patient Population
Vascular
Bed
Marker of Endothelial
Function End Points Examined Findings
Al Suwaidi (27) Retrospective/28 months 157 patients with mild CAD Coronary Acetylcholine response Cardiac death, MI, CHF,
CABG, or PCI
6 patients with event. Acetylcholine
response independent predictor of
events.
Schachinger (28) Retrospective/7.7 years 147 patients with CAD Coronary Acetylcholine, cold pressor
test, FMD, NTG
MI, UA, ischemic stroke, CABG,
PTCA, peripheral bypass
28 patients with event. Vasomotor
function independent predictor of
events.
Neunteufl (31) Retrospective/5 years 73 patients with CAD Brachial FMD Death, MI, PTCA, or CABG 27 patients with event. FMD
10% predictive of events. Effect
lost when controlling for extent of
CAD.
Heitzer (30) Prospective/4.5 years 281 patients with CAD Brachial Forearm blood flow response
to acetylcholine
CVD death, stroke, MI, CABG,
PTCA, peripheral bypass
91 patients with event. Acetylcholine
response independent predictor of
events.
Perticone (34) Prospective/32 months 225 patients with
hypertension
Brachial Forearm blood flow response
to acetylcholine
CVD death, MI, stroke, TIA,
UA, CABG, PTCA, PVD
29 subjects with event. Acetylcholine
response predictive of events.
Gokce (32) Prospective/30 days 187 patients undergoing
vascular, surgery
Brachial FMD CVD death, MI, UA, stroke 45 patients with event. FMD
independent predictor of events.
Modena (35) Prospective/67 months 400 hypertensive post-
menopausal women
Brachial FMD Hospitalization for CVD event
(not otherwise specified)
47 patients with event. Failure to
improve FMD with 6 months of
antihypertensive therapy
independent predictor of events.
Halcox (29) Retrospective/46 months 308 patients referred for
cardiac catheterization
Coronary Acetylcholine response CVD death, MI, ischemic stroke,
UA
35 subjects with event. Acetylcholine
response independent predictor of
events.
Schindler (36) Prospective/45 months 130 patients with normal
coronary angiograms
Coronary Cold presser test CVD death, UA, MI, PTCA,
CABG, stroke, peripheral
bypass
26 patients with event. Cold pressor
test response independent
predictor of events.
Gokce (33) Prospective/1.2 years 199 patients undergoing
vascular surgery
Brachial FMD CVD, death, MI, UA, stroke 35 patients with events. FMD
independent predictor of long-
term events.
CABG coronary artery bypass graft surgery; CAD coronary artery disease; CHF congestive heart failure; CVD cardiovascular disease; FMD flow-mediated dilation; MImyocardial infarction; NTG nitroglycerin-mediated
dilation; PCI  percutaneous coronary intervention (e.g., angioplasty or stent); PTCA  percutaneous transluminal coronary angioplasty; PVD  peripheral vascular disease; TIA  transient ischemic attack; UA  unstable angina.
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mation, including increased levels of C-reactive protein (7),
are also associated with endothelial dysfunction in human
subjects (8,42,43). Overall, these studies illustrate that
identifying endothelial phenotype using systemic markers
has prognostic value. It remains unknown which individual
marker or combination of markers will prove most useful.
Interventions to reverse endothelial dysfunction. An im-
portant corollary to the hypothesis that endothelial dysfunc-
tion contributes to the pathogenesis of CVD is the idea that
reversing endothelial dysfunction will reduce risk. Although
this corollary has not been tested directly, numerous studies
have evaluated lifestyle and pharmacologic interventions to
improve endothelial function, and many of these same
interventions are known to limit cardiovascular risk. The
effects of some of these treatments on endothelial function
and CVD risk are summarized in Table 4.
Lifestyle modification. Exercise is an important lifestyle
factor that reduces cardiovascular risk (44), and exercise has
been repeatedly shown to improve endothelial vasomotor
function in healthy subjects (45,46) and in disease states
including hypertension (47), congestive heart failure (48),
and CAD (49). These effects appear to be mediated in large
part by increased NO bioavailability (50) and may be
greatest in vascular beds exposed to repetitive increases in
blood flow during exercise (51), which includes the coronary
circulation for all types of exercise.
In contrast, a sedentary lifestyle is linked to obesity and is
associated with endothelial dysfunction, increased oxidative
stress, and elevated systemic markers of inflammation. In
obese women, a yearlong program of low fat diet and
exercise reduced plasma levels of tumor necrosis factor-
alpha, interleukin-6, soluble ICAM-1, and soluble vascular
cell adhesion molecule-1 (VCAM-1) (52). In that study,
weight loss improved “endothelial function” as reflected by
the degree of BP reduction after infusion of L-arginine. No
published study has examined the effects of weight loss on
endothelium-dependent vasodilation. Minimizing other
traditional risk factors for CVD also improves endothelial
function. For example, BP reduction (35), drug therapy to
increase insulin sensitivity in diabetics (53), and smoking
cessation (54) have been associated with improved endothe-
lial function.
Dietary modifications. Diets low in fat and high in fruits
and vegetables have been recommended by the American
Heart Association to decrease cardiovascular risk (55). A
portion of the benefit could result from increased intake of
flavonoids, which may improve endothelial function. For
example, endothelial dysfunction is reversed after intake of
flavonoid-containing beverages including tea (56) grape
juice (57), and de-alcoholized red wine (58).
Conversely, poor dietary habits may worsen endothelial
function. Several studies suggest that a high-fat meal will
induce acute impairment of FMD (59), although a portion
of this effect may relate to other non-endothelium-
dependent systemic effects on the vasculature (60). The type
of fat consumed may also be important (61), as a diet high
in n-3 fatty acids (i.e., fish oil) may improve endothelium-
dependent vasodilation (62).
Antioxidant therapy. Oxidative stress is a central cause of
endothelial dysfunction in atherosclerosis (63), and there
has been great interest in the effects of antioxidant therapy.
Regarding lipid-soluble antioxidants, probucol combined
with lovastatin improved coronary endothelial function in
patients with CAD (64). However, the data for vitamin E
are quite mixed (reviewed by Duffy et al. [65]). Vitamin E
has been shown to improve endothelial function in patients
with multiple risk factors, particularly cigarette smoking
(66). However, a number of other studies have failed to
show a benefit (67–70). These latter results may be consis-
tent with the recently published Heart Outcomes Preven-
tion Evaluation (HOPE) study (71), which failed to dem-
onstrate any effect of vitamin E on CVD events in a
large-scale randomized trial.
Regarding water-soluble antioxidants, vitamin C admin-
istration consistently improves endothelium-dependent va-
sodilation in patients with CVD (65). Some epidemiologic
studies suggest that individuals with low plasma concentra-
tions (72) or low dietary intake (73) of ascorbic acid have
increased cardiovascular risk. However, no randomized
clinical trial has addressed the benefits of ascorbic acid
treatment in a patient population with evidence of inade-
quate ascorbic acid intake or unsaturated tissue stores.
Studies of combinations of antioxidants, typically vitamin
C, vitamin E, and beta-carotene, have provided disappoint-
ing results. Two studies failed to demonstrate a beneficial
Table 4. Effect of Interventions on Endothelial Function and
CVD
Intervention
Effect on
Endothelial
Function
Effect on
CVD Events
Lipid-lowering therapy  
Smoking cessation  
Exercise  
ACE inhibitors  
Angiotensin receptor blockers  
N-3 fatty acids  
Glycemic control in diabetes mellitus  
Hormone replacement therapy  
Vitamin E  
Combination antioxidants  
L-arginine  ?
Dietary flavonoids  ?
Vitamin C  ?
Folate  ?
Tetrahydrobiopterin  ?
Specific metal ion chelation therapy  ?
Protein kinase C inhibition  ?
Cyclooxygenase-2 inhibition  ?
Thromboxane A2 inhibition  ?
Troglitazone treatment in diabetes  ?
Xanthine oxidase inhibition  ?
Tumor necrosis factor inhibition  ?
  weight of evidence indicates an improvement;   weight of evidence indicates
no effect or worsening; ?  there are insufficient data at the present time.
ACE  angiotensin converting enzyme; CVD  cardiovascular disease.
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effect of this combination on endothelium-dependent vaso-
dilation (74,75). The recent Heart Protection Study exam-
ined such a combination in 20,536 individuals with CAD,
diabetes, or peripheral vascular disease and demonstrated no
benefit on cardiovascular events (76).
Despite the strong evidence that oxidative stress contrib-
utes to atherogenesis (77) and endothelial dysfunction (63),
there are a number of possible reasons why antioxidant
treatment has failed to show a benefit. For example, the
studied antioxidants may have insufficient activity against
the, as yet, undefined oxidants most relevant to CVD and
endothelial dysfunction. The background antioxidant status
of participants may have obscured any beneficial effect.
Finally, it is possible that an antioxidant strategy designed to
act on the sources of oxidant stress may be more effective
than treatment with agents that act on selected “down-
stream” consequences, as has been suggested by Mu¨nzel and
Keaney (78).
Lipid-lowering therapy. There is strong and consistent
evidence that reduction of plasma low-density lipoprotein
improves endothelial function. This benefit has been ob-
served when low-density lipoprotein is lowered by non-
pharmacologic means such as diet in animals (79), and with
bile acid resins and plasma apheresis in humans (80,81).
Treatment with HMG CoA reductase inhibitors (statins)
has been consistently shown to reduce cardiovascular risk
(82) and reverse endothelial dysfunction (64,80,83–86).
Although two studies have failed to demonstrate a benefit
on coronary endothelial function, these studies involved
short-term treatment of patients with relatively low baseline
cholesterol levels and had methodological problems includ-
ing limited statistical power and improved endothelial
function in the placebo group (87,88). While statins have
been shown to induce regression of atherosclerotic plaques,
the available data strongly suggest that that the interrelated
effects of statins on the endothelium, inflammation, and
plaque composition are more important than lesion regres-
sion in regard to the observed reduction in cardiovascular
risk (12).
While reduction of serum cholesterol is likely the major
mechanism by which statins improve endothelial function,
in vitro studies suggest that pleiotropic effects of statins may
also be relevant. In addition to reducing cholesterol levels,
HMG CoA reductase inhibition reduces cellular concentra-
tions of important and biologically active intermediates that
influence endothelial phenotype. By this mechanism, statins
have been shown to directly enhance expression, phosphor-
ylation state, and activity of the endothelial isoform of NO
synthase (89,90). Moreover, C-reactive protein reduces NO
synthase expression (91), suggesting that statins may spe-
cifically protect against the adverse effects of inflammation
on the vasculature. It remains uncertain whether the pleio-
tropic effects of statins are relevant at the concentrations of
statins achievable in patients.
Angiotensin-converting enzyme inhibition and angio-
tensin-II receptor blockade. Large-scale outcome trials
(92) have clearly demonstrated that angiotensin-converting
enzyme (ACE) inhibitors reduce CVD events in patients
with CAD and diabetes, independent of BP reduction.
Similarly, ACE inhibitors also improve endothelial function
(93–96). Angiotensin converting enzyme inhibitors may
affect endothelium-derived NO by several mechanisms. For
example, angiotensin-II increases nicotinamide adenine
dinucleotide phosphate (reduced) oxidase activity (97) lead-
ing to increased production of reactive oxygen species and
“inactivation” of NO. Furthermore, ACE inhibitors inhibit
the breakdown of bradykinin, a substance that stimulates
NO production. Indeed, investigators have proposed that
the balance between angiotensin II and NO is one of the
major determinants of endothelial and vascular phenotype
(98). The importance of angiotensin-II is further supported
by the observation that angiotensin receptor blockers also
appear to improve endothelial function and reduce endo-
thelial markers of inflammation and oxidative stress
(99,100).
Hormone replacement therapy. There has been extensive
study of hormone replacement therapy (HRT) and endo-
thelial function (101). Studies in post-menopausal women
have repeatedly shown that estrogen replacement improves
endothelium-dependent dilation and reduces systemic plas-
minogen activator inhibitor-1 levels (102). Combination
therapy with a progesterone preparation blunts the benefits
of estrogen in some, but not all studies (103,104). The issue
of whether estrogen treatment has a beneficial effect on
endothelial function in patients with established CVD has
been less well studied, but a large cross-sectional study
suggests that the beneficial effects are less than those
observed in younger women without CVD (105). Despite
the apparent beneficial effects on endothelial function,
outcome studies have failed to show a beneficial effect of
HRT (combination of estrogen and progesterone) for pri-
mary (106) or secondary (107) prevention of CVD events.
Indeed, reduction in cardiovascular risk is no longer an
accepted indication for HRT.
The explanations for the apparently disparate results
remain uncertain. However, estrogen and progesterone have
complex cellular effects, and it is possible that adverse
effects, including pro-thrombotic effects, outweigh the ben-
efits of improved endothelial function. Furthermore, it is
unclear whether benefits of estrogen might have been
confounded by concurrent progesterone therapy. Neverthe-
less, these results suggest that not every therapy that
improves endothelial function translates directly into a
reduction in cardiovascular risk.
Newer interventions. Finally, a number of newer therapies
have been shown to improve endothelial function in human
subjects, and a partial list is provided in Table 4. For
example, L-arginine, which is the precursor for NO syn-
thesis, has been administered in high doses to human
subjects and has been shown in some studies to improve
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endothelium-dependent dilation (108,109). Other examples
include tetrahydrobiopterin, an essential co-factor for endo-
thelial NO synthase (110), protein kinase C inhibition
(111), iron chelation (112), and cyclooxygenase-2 inhibition
(113). It is likely that many additional therapies will emerge
as the pathophysiologic mechanisms of endothelial dysfunc-
tion in specific disease states are elucidated.
Clinical utility of studying endothelial function. In sum-
mary, the reviewed studies suggest that: 1) the endothelium
plays a central role in vascular homeostasis and the patho-
genesis of CVD; 2) endothelial vasomotor function can
readily be measured in the coronary and peripheral circula-
tions and that systemic markers of endothelial phenotype
can be measured in blood; 3) endothelial vasomotor dysfunc-
tion detected in the coronary or peripheral circulation has
prognostic value; and 4) many, but not all, interventions that
reverse endothelial dysfunction also reduce cardiovascular risk.
The question at hand is how these results can be used from a
public health and/or clinical perspective (Table 5).
The available evidence suggests that endothelial function
reflects the integrated effects of risk factors on the vascula-
ture and that the development of endothelial dysfunction is
an early event in the atherogenic process. There are strong
and consistent relationships between mechanistically diverse
risk factors and endothelial dysfunction. Furthermore, en-
dothelial dysfunction identifies individuals at risk, before the
development of clinically apparent CVD. These observa-
tions suggest that study of endothelial dysfunction has
utility for the identification of novel risk factors for CVD.
The finding that a potential risk factor is associated with
endothelial dysfunction in carefully controlled cross-
sectional studies would strongly suggest that this factor is
associated with the development of CVD. Further evidence
would be provided by studies showing the reversal of
endothelial dysfunction by a specific intervention also re-
duces the cardiovascular risk associated with the risk factor.
Often such studies are performed in the context of support-
ive epidemiologic outcome studies and mechanistic basic
studies suggesting a causal relationship between the risk
factor and atherosclerosis. Recent examples of the utility of
endothelial function in regard to novel risk factors include
obesity (6) and certain systemic infections (8).
Another current role for study of endothelial dysfunction
is evaluation of interventions to reduce CVD risk. There is
great interest in identifying “surrogate markers” of risk that
can be used as an end point to evaluate a potential
intervention before undertaking a longer term and consid-
erably more expensive study that involves CVD events as
the end point. Given the prognostic value of endothelial
dysfunction and the strong correlation between improved
endothelial dysfunction and reduced cardiovascular risk
(Table 4), it is reasonable to consider endothelial dysfunc-
tion for this purpose. The possibility of using endothelial
function to screen patients for evidence of high cardiovas-
cular risk is further supported by high sensitivity and
negative predictive values (90%, respectively) (32). Again,
studies evaluating the utility of endothelial function as a
screening test must be evaluated in the context of other
available epidemiologic, clinical, and experimental data. As
is the case for HRT, potential confounding effects of the
intervention must be considered.
A number of other modalities have been considered
potential surrogate end points for CVD, including carotid-
intimal thickness measured by ultrasound and coronary
calcification assessed by computed tomography or magnetic
resonance imaging scan. These modalities largely provide a
measure of the presence and extent of fixed atherosclerosis.
Studies of endothelial function may prove advantageous
because they provide insight into vascular function, which
appears to be more relevant to the pathogenesis of plaque
rupture and the ensuing thrombosis that underlies cardio-
vascular events. Measurement of serum markers of inflam-
mation (e.g., C-reactive protein) is another promising ap-
proach to this issue, but may not reflect the susceptibility of
the vasculature to the adverse effects of systemic inflamma-
tion. It is possible that the state of the endothelium may
reflect the degree to which the vasculature has been altered
by inflammatory stimuli, and, thus, may provide additional
prognostic information. Also unknown is the potential role
of more specific serum markers of endothelial dysfunction
such as plasminogen activator inhibitor-1, endothelin, and
adhesion molecules (ICAM-1, VCAM-1). Direct compar-
ative studies of the relative utility of available surrogates are
lacking at the present time.
The available studies linking endothelial dysfunction to
cardiovascular events (Table 3) raise the intriguing possibil-
ity that the technique could have utility for the management
of individual patients. In regard to brachial artery FMD,
studies of patients with hypertension and established coro-
nary disease suggest that endothelial dysfunction identifies
individuals who might benefit from more intensive treat-
ment (31,35). Similarly, the prospective studies by Gokce et
al. (32,33) might suggest that patients with peripheral
arterial disease with preserved endothelial function are at
low risk for perioperative and long-term events and might
be managed differently than patients with poor function.
The study by Modena et al. (35) raises the further possibility
that persistent endothelial dysfunction during antihyperten-
Table 5. Clinical Utility of Endothelial Dysfunction
Current uses
Identification of novel risk factors for CVD
Investigation of mechanisms of atherosclerosis and vascular
dysfunction
Surrogate marker of cardiovascular risk for intervention studies
involving groups of patients
Potential future uses
Screening individuals for future cardiovascular risk
Evaluating CVD patients for lifestyle, pharmacologic, and/or
mechanical intervention
Preoperative evaluation
Monitoring response to primary and secondary prevention therapies/
strategies
CVD  cardiovascular disease.
1156 Widlansky et al. JACC Vol. 42, No. 7, 2003
Endothelial Dysfunction October 1, 2003:1149–60
sive therapy identifies high-risk individuals and that endo-
thelial function might be used to monitor the effectiveness
of risk reduction therapy. Thus, evaluation of endothelial
function could be advantageous in prevention of both
primary and secondary events. A paradigm shift from the
current reactive, symptom-based, screening system looking
for active disease to a non-invasive, relatively inexpensive,
screening system based on vascular function would also be of
benefit to both the general health of the population and the
already overburdened and costly medical system.
Although highly appealing, there are insufficient data to
support these possible applications for individual patients at
the present time. Reproducible evaluation of endothelial
function is limited to facilities with extensive experience in
these techniques. The applicability of testing endothelial
function on a population-wide basis is further diminished by
the lack of large prospective trials evaluating its efficacy as a
screening tool in the general population and by the lack of
trials demonstrating that improving endothelial function
decreases cardiovascular risk. Further studies are needed to
confirm the available results and to carefully evaluate the
sensitivity and specificity of the techniques relative to or in
combination with other available measures of risk for
individual patients. The recently initiated Multi-Ethnic
Study of Atherosclerosis (MESA) will clarify some of these
issues by simultaneously examining the predictive value of
several measures of endothelial function and other subclin-
ical markers of atherosclerosis (114). However, further
studies are needed to demonstrate that clinical use of
endothelial function can be used to guide risk reduction
therapy.
Future directions. The available methods for studying
endothelial function are currently useful for evaluating risk
factors, mechanisms of CVD, and potential interventions in
groups of patients. However, as outlined in Table 2, there
are important limitations associated with each of these
techniques. Development of improved or novel methodol-
ogy to assess endothelial vasomotor function would be
extremely useful. One approach would be to develop a
means to obtain higher-resolution imaging of arterial diam-
eter. Ideally, such imaging would be performed in the
coronary circulation, although the available data indicate
that peripheral arteries are reasonable surrogates. The most
current non-invasive methodology requires off-line analysis,
and another potential advance would be the development of
continuous on-line measurement and reporting of vasomo-
tor responses. At the present time, study of nitric-oxide-
dependent responses requires imaging of blood vessels,
measurement of changes in blood flow, or pulse wave
analysis. Development of simpler indirect methods to assess
endothelium-dependent responses may hold some promise
for the future. For example, there is recent interest in a
simple pulse amplitude tonometry method to measure
FMD of small vessels in the finger (115–117). There also
may be utility in further study of other manifestations of the
pathologic endothelial phenotype, including pro-
thrombotic, vasoconstrictor, and pro-inflammatory factors
that can be measured in blood. Most important for the
future use of endothelial function in the care of patients is
the need for a standardized approach that is supported by
large-scale outcome studies.
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